Navigation Links
BioMS Medical Announces 2007 Year End Results
Date:3/18/2008

consultant review.

Financial Results

The consolidated net loss for the year ended December 31, 2007 was $47.2 million or ($0.56) per share compared with a consolidated net loss of $40.9 million or ($0.62) per share for the previous year. The consolidated net loss for the fourth quarter ended December 31, 2007 was $11.7 million or ($0.13) per share compared with a consolidated net loss of $14.1 million or ($0.20) per share for the fourth quarter of the previous year.

Total consolidated expenses for the year ended December 31, 2007 were $48.0 million compared to $42.2 million for the previous year. Total consolidated expenses for the three months ended December 31, 2007 were $12.1 million compared to $14.4 million for the same quarter of the previous year.

Research and development expenses for the year ended December 31, 2007 totaled $38.9 million compared with $35.2 million in 2006. The increase was due primarily to the start up and initial enrollment of patients in the MAESTRO-02 follow-on trial, the full enrollment and continuation of the MINDSET-01 clinical trial and the start-up and commencement of enrolment of the MAESTRO-03 clinical trial. It is expected that research and development expenses will increase over the next two years as the current clinical trials for MBP8298; MAESTRO-01, MAESTRO-02, MAESTRO-03 and MINDSET-01, continue in Canada, Europe and the U.S.

Research and development expenses were $9.3 million for the fourth quarter ended December 31, 2007 compared to $12.5 million for the fourth quarter of the previous year. The reduction in expenses was the net result of reduced costs for the MAESTRO-01 trial, as more patients are completing or near completion of their two years on the trial, and a reduction in the number of batches of MBP8298 manufactured in the year, offset by start-up costs for the MAESTRO-02 and MAESTRO-03 trials.

General and administrative expenses were $7.5 million for the year ended December
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at BioContact 2007
9. BioMS Medical announces its intention to renew a normal course issuer bid
10. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
11. GHI Medical Deploys New Test to Help Determine Hair Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... VANCOUVER , Aug. 26, 2015 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... continue pre-clinical activities with respect to our Oral ... of a contract manufacturer," said Andrew Rae ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
(Date:8/25/2015)... SHANGHAI , Aug. 25, 2015   WuXi ... open-access R&D capability and technology platform company serving the ... Holdings Ltd. ("Lee,s Pharm," Hong Kong Exchange Stock Code: ... Hong Kong with 20 years of operations ... the two companies have signed an agreement whereby WuXi,s ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... CLARA, Calif., Oct. 10 Finesse Solutions, LLC, ... science process,applications, is pleased to announce improvements to ... transmitters even easier. The E-Store,can be found at ... now easily purchase bioprocess sensors and accessories,on-line, anywhere ...
... England, Oct. 10 Twenty of Britain,s most,innovative ... their,ideas at the fifth annual SETsquared Partnership Showcase ... Great George Street, London, from 8am on,Thursday, October ... electronics, information technology, engineering and biotechnology., Six ...
... October 10 , - Ranked Number 7 out ... Merck Serono, a division of Merck KGaA, Darmstadt, Germany, ... as a top employer in the,biotechnology and pharmaceutical industries, ... the life sciences., "We are honored that the ...
Cached Biology Technology:Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 2Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 3Merck Serono Named as a Top Employer by Science Magazine 2
(Date:8/12/2015)... , August 12, 2015 As ... mobile payment innovation and advanced biometrics technology is accelerating ... way consumers rely on using their credit cards, the ... the future for payment services led by companies in ... ), :  Google, Inc. (NASDAQ: GOOG ), Apple ...
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... 2011 Recent studies conducted at the Institut de ... PCSK enzymes could have a positive impact on health, ... Nabil G. Seidah, Director of the Biochemical Neuroendocrinology research ... over the past four months, all shedding light on ...
... on cancer, and development of new cancer therapeutics, has ... area of focus is the life and death of ... programmed cell death, is a fundamental process of cells ... apoptosis involve many different proteins and their interactions with ...
... plant species on the Iberian Peninsula had been discovered, ... Taraxacum lacianense , two dandelions from the Pyrenees ... confirms Spain,s privileged position as a hotbed of biodiversity. ... Spain. It depends on the complexity of the group ...
Cached Biology News:1 group of enzymes could have a positive impact on health, from cholesterol to osteoporosis 21 group of enzymes could have a positive impact on health, from cholesterol to osteoporosis 3Designing new molecular tools to study the life and death of a cancer cell 2Designing new molecular tools to study the life and death of a cancer cell 3Designing new molecular tools to study the life and death of a cancer cell 42 new plants discovered in Spain 2
... of the human Topoisomerase II gene. ... state of nucleic acids by passing an intact ... a separate DNA helix (1,2) . As a ... enzyme can relax negatively or positively supercoiled DNA, ...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
... Kit - Monolayer is a system designed for ... monolayer in a serum-free environment. The kit contains ... has been optimized for neural stem cell expansion ... & Development 10 :3129). Human fibroblast growth ...
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
Biology Products: